Cybin Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYBN research report →
Companywww.cybin.com
Cybin Inc. , a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation.
- CEO
- Eric So
- IPO
- 2019
- Employees
- 50
- HQ
- Toronto, ON, CA
Price Chart
Valuation
- Market Cap
- $413.02M
- P/E
- -1.38
- P/S
- 0.00
- P/B
- 0.66
- EV/EBITDA
- 0.63
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -61.47%
- ROIC
- -50.70%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-113,137,000 · -44.90%
- EPS
- $-0.61 · 93.58%
- Op Income
- $-143,147,000
- FCF YoY
- -48.33%
Performance & Tape
- 52W High
- $10.72
- 52W Low
- $4.81
- 50D MA
- $6.69
- 200D MA
- $6.99
- Beta
- 0.79
- Avg Volume
- 874.38K
Get TickerSpark's AI analysis on CYBN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CYBN Coverage
View all →
Want a deeper read on CYBN?
Generate a full analyst-grade report — bull / bear case, price targets, valuation depth, and a complete financial breakdown.